| Title : Plasma Cholinesterase Activity in Alzheimer's Disease - Hosoi_2015_Neurodegener.Dis_15_188 |
| Author(s) : Hosoi M , Hori K , Konishi K , Tani M , Tomioka H , Kitajima Y , Akashi N , Inamoto A , Minami S , Izuno T , Umezawa K , Horiuchi K , Hachisu M |
| Ref : Neurodegener Dis , 15 :188 , 2015 |
|
Abstract :
Cholinesterase inhibitors (ChEIs) are not allowed to be prescribed in combination, which means that we need to select 1 of 3 ChEIs for use in a patient with Alzheimer's disease (AD). However, there is no quantitative analysis on the differences between these agents. In this article, we propose that plasma cholinesterase activity (pChE) could be used as the standard for differentiating between rivastigmine (Riv) and donepezil (Don) in the management of AD. To date, we have treated 6 patients with Riv 18 mg and 5 patients with Don 5 mg. The pChE is related to low-grade inflammation associated with AD, diabetes mellitus and lipid metabolic dysfunction. Moreover, low pChE is related to liver dysfunction. The pChE must be kept under control. We speculated that Riv is the most appropriate therapy for patients with relatively high pChE, whereas Don is best reserved for those AD patients with relatively low pChE. (c) 2015 S. Karger AG, Basel. |
| PubMedSearch : Hosoi_2015_Neurodegener.Dis_15_188 |
| PubMedID: 26138498 |
Hosoi M, Hori K, Konishi K, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Minami S, Izuno T, Umezawa K, Horiuchi K, Hachisu M (2015)
Plasma Cholinesterase Activity in Alzheimer's Disease
Neurodegener Dis
15 :188
Hosoi M, Hori K, Konishi K, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Minami S, Izuno T, Umezawa K, Horiuchi K, Hachisu M (2015)
Neurodegener Dis
15 :188